Last updated: April 29, 2026
What Happened in Shire LLC v. Ranbaxy Inc. (1:14-cv-00827): Litigation Summary and Patent-Strategy Takeaways
What court and case posture applied in Shire LLC v. Ranbaxy Inc. (1:14-cv-00827)?
The matter is styled Shire LLC (plaintiff) v. Ranbaxy Inc. (defendant) and is docketed as 1:14-cv-00827 in the U.S. federal district system. The case number identifies a 2014-filed action in federal court.
A complete litigation summary requires record-level details (asserted patent(s), claim construction outcomes, motion practice, trial or settlement posture, and final judgment). Those specifics are not present in the information provided here, so a full accuracy-compliant analysis of the merits and procedural endpoints cannot be produced.
What was at stake in the dispute (patents, claims, and accused conduct)?
A litigation analysis depends on three data points:
- Asserted patent(s) and their expiration/OTC status (e.g., Orange Book listings, regulatory triggers).
- Accused product identification (ANDA or other regulatory submission, composition and labeling).
- Allegations and defenses (infringement theories, invalidity grounds such as anticipation/obviousness, or statutory bars).
This information is not included in the prompt. Without it, any attempt to specify patents-in-suit, infringement theories, or validity challenges would be incomplete and could misstate the record.
What procedural milestones typically determine the strategic read-through?
For cases of this docket type (filed in 2014), the strategic read-through usually turns on:
- Whether the case resolved through settlement vs. merits adjudication
- Whether claim construction was issued
- What the court did on preliminary injunctive relief (if any)
- Whether final judgment entered on infringement/invalidity or stayed pending other proceedings
None of these milestones are provided.
What business implications can be drawn without the record?
No record details are available here, so the only defensible implications are structural:
- The case is part of the defensive competitive landscape around brand-and-generic patent thickets.
- The posture likely involved patent infringement allegations tied to an FDA regulatory pathway given the defendant’s typical business profile, but the exact procedural and regulatory link cannot be stated accurately without the docket’s substance.
What patent litigation lessons apply as a framework?
Even without the case-specific record, Shire-side and Ranbaxy-side strategies in this class of matters generally map to:
- Claim scope discipline (how narrowing constructions can align or defeat infringement theories)
- Validity targeting (prior-art selection, obviousness combinations, and secondary considerations)
- Regulatory timing (how stays and 30-month injunction frameworks influence negotiation windows)
- Settlement economics (license terms, launch dates, and compensation structures)
However, applying these to this docket requires case-specific findings (what the court construed, which prior art was used, and what claims survived). Those findings are not present.
Key Takeaways
- The case is identified as Shire LLC v. Ranbaxy Inc., 1:14-cv-00827, filed in 2014.
- A litigation summary and patent-strategy analysis require asserted patents, accused product/regulatory pathway, and disposition record.
- Those record elements are not included in the provided input, so a complete and accuracy-compliant analysis cannot be produced here.
FAQs
1) What court handled Shire LLC v. Ranbaxy Inc., 1:14-cv-00827?
The prompt identifies the matter by docket number only; it does not include the court.
2) What patents were asserted in the case?
The prompt does not list the patents-in-suit.
3) Was the case decided on the merits or resolved by settlement?
The prompt does not include the case disposition.
4) What was the final outcome (infringement, invalidity, injunction, or dismissal)?
The prompt does not include the final judgment or order.
5) Does the case relate to an ANDA and Orange Book patents?
The prompt provides no information linking the dispute to an ANDA or Orange Book listing.
References
[1] Docket entry identifiers for Shire LLC v. Ranbaxy Inc., 1:14-cv-00827 (not provided in the prompt content).
